Pharma
Weight loss drugs boom drives pharma R&D returns, but industry could face ‘bubble’ effect
Top global pharma companies’ return on R&D increased for third consecutive year; Growth is almost entirely driven by GLP-1 drugs - used to treat obesity and diabetes - and accounts for 38% of projected sales;Obesity drugs have displaced oncology drugs as the largest contributor to t...
12 gene therapies converge on retinitis pigmentosa and a $3.4bn market by 2033
This month Gene Scope Intelligence (www.genescope-intelligence.com), a dedicated gene therapy market intelligence platform releases a brand new commercial analysis and demand forecast for new gene therapies directed at Retinitis Pigmentosa (RP). ...
Patient Engagement & Communication Drop-in with PhiZ & Co.
How do you ensure your research, clinical plans, and communications reflect what matters most to patients?Whether you're in early discovery, preparing for clinical development, or already running studies, bringing in patient insight early can help strengthen decisions, improve study des...
The Common Thread — Monthly Networking Morning
Kickstart your day by connecting with brilliant people and opening doors to new opportunities.Join us at University Arms, in collaboration with the wonderful Neil Bharadwa at The Cambridge Fruit Company, for The Common Thread. A relaxed monthly networking morning bringing together Cambr...
The Common Thread — Monthly Networking Morning
Kickstart your day by connecting with brilliant people and opening doors to new opportunities.Join us at University Arms, in collaboration with the wonderful Neil Bharadwa at The Cambridge Fruit Company, for The Common Thread. A relaxed monthly networking morning bringing together Cambr...
Isogenica Ltd. and Axxam S.p.A. Announce Collaboration to Provide Unique VHH Antibody Discovery Solutions
Axxam S.p.A. and Isogenica Ltd. have announced a partnership to bring together functional bioassay capabilities with unique antibody discovery solutions for biotechnology and pharmaceutical clients. ...
Isogenica and Cube Biotech Unite to Accelerate GPCR Therapeutics
Isogenica, a global leader in synthetic VHH antibody discovery, has announced a strategic collaboration with Cube Biotech, experts in stabilised protein technologies, to tackle one of the most complex challenges in drug discovery: G protein-coupled receptors (GPCRs). ...
From Hit to Clinic: Isogenica and Charles River Collaborate to Accelerate Next-Generation Peptide and VHH Discovery
Every breakthrough begins with discovery. Isogenica, a leader in synthetic VHH antibody and peptide discovery, has announced a collaboration with Charles River, a leading, global provider of drug discovery, development, and manufacturing solutions, to help biotech companies streamline d...
Cerberus Therapeutics Enters into Antibody Discovery Agreement with Isogenica to Advance Immune-Modulating Therapies
Isogenica Ltd., The VHH Company™, today announced an antibody discovery agreement with Cerberus Therapeutics to support the development of targeted immune-modulating therapies using single-domain antibodies. This agreement brings together Cerberus’s KappaLink™ platform — designed to en...
Webinar: Advanced Pharmacophore Searching Across the CSD and PDB: Improved Features in CSD-CrossMiner
The CSD-CrossMiner allows you to build pharmacophore queries and simultaneously search the CSD, PDB, and your own proprietary structural data. This helps you quickly identify off‑target effects, alternative scaffolds, similar binding sites, interaction motifs, bioisosteres, and more. ...